Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bofanglutide

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326

NCT06737042

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
24 mg GZR18 groupn/rn/rn/rn/r
36 mg GZR18 groupn/rn/rn/rn/r
48 mg GZR18 groupn/rn/rn/rn/r
Tirzepatide groupn/rn/rn/rn/r

Not shown

  • 24 mg GZR18 group: endpoint not reported
  • 36 mg GZR18 group: endpoint not reported
  • 48 mg GZR18 group: endpoint not reported
  • Tirzepatide group: endpoint not reported